Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 320

1.

Survivin expression as a prognostic factor in patients with epithelial ovarian cancer or primary peritoneal cancer treated with neoadjuvant chemotherapy.

Gąsowska-Bodnar A, Bodnar L, Dąbek A, Cichowicz M, Jerzak M, Cierniak S, Kozłowski W, Baranowski W.

Int J Gynecol Cancer. 2014 May;24(4):687-96. doi: 10.1097/IGC.0000000000000108.

PMID:
24662134
2.

Improved survival trends in platinum-resistant patients with advanced ovarian, fallopian or peritoneal cancer treated with first-line paclitaxel/platinum chemotherapy: the impact of novel agents.

Bamias A, Bamia C, Zagouri F, Kostouros E, Kakoyianni K, Rodolakis A, Vlahos G, Haidopoulos D, Thomakos N, Antsaklis A, Dimopoulos MA.

Oncology. 2013;84(3):158-65. doi: 10.1159/000341366.

PMID:
23296063
3.

BRCA1 expression and improved survival in ovarian cancer patients treated with intraperitoneal cisplatin and paclitaxel: a Gynecologic Oncology Group Study.

Lesnock JL, Darcy KM, Tian C, Deloia JA, Thrall MM, Zahn C, Armstrong DK, Birrer MJ, Krivak TC.

Br J Cancer. 2013 Apr 2;108(6):1231-7. doi: 10.1038/bjc.2013.70.

4.

The prognostic significance of the immunohistochemical expression of p53, bcl-2, c-erb B-2 and cathepsin-D in ovarian cancer patients receiving platinum with cyclophosphamide or paclitaxel chemotherapy.

Protopapas A, Diakomanolis E, Bamias A, Milingos S, Markaki S, Papadimitriou C, Dimopoulos AM, Michalas S.

Eur J Gynaecol Oncol. 2004;25(2):225-9.

PMID:
15032288
5.
6.

Primary chemotherapy for inoperable ovarian, fallopian tube, or primary peritoneal cancer with or without delayed debulking surgery.

Saha A, Varughese M, Gallagher CJ, Orphanos G, Wilson P, Oram D, Jeyarajah A, Reynolds K, Shepherd J, McCormack M, Olaitan A, McDonald N, Mould T, McNeish I, Ledermann JA.

Int J Gynecol Cancer. 2012 May;22(4):566-72. doi: 10.1097/IGC.0b013e318247727f.

PMID:
22426404
7.

Multiple Cycles of Neoadjuvant Chemotherapy Associated With Poor Survival in Bulky Stage IIIC and IV Ovarian Cancer.

Ren Y, Shi T, Jiang R, Yin S, Wang P, Zang R.

Int J Gynecol Cancer. 2015 Oct;25(8):1398-404. doi: 10.1097/IGC.0000000000000517.

PMID:
26222486
8.

Treatment outcomes of paclitaxel for refractory or recurrent epithelial ovarian cancer patients in Thailand.

Pitakkarnkul S, Tangjitgamol S, Srijaipracharoen S, Manusirivithaya S, Pataradool K, Prutthiphongsit W, Khunnarong J, Thavaramara T.

Asian Pac J Cancer Prev. 2013;14(4):2421-7.

9.

The relationship of platinum resistance and ERCC1 protein expression in epithelial ovarian cancer.

Steffensen KD, Waldstrøm M, Jakobsen A.

Int J Gynecol Cancer. 2009 Jul;19(5):820-5. doi: 10.1111/IGC.0b013e3181a12e09.

PMID:
19574766
10.

Role of neoadjuvant chemotherapy in the management of advanced ovarian cancer.

Zhao D, Wu LY, Wang XB, Li XG.

Asian Pac J Cancer Prev. 2015;16(6):2369-73.

11.

Prognostic factors and clinical outcome of patients with recurrent early-stage epithelial ovarian cancer: an Italian multicenter retrospective study.

Gadducci A, Cosio S, Zola P, Sostegni B, Fuso L, Sartori E.

Int J Gynecol Cancer. 2013 Mar;23(3):461-8. doi: 10.1097/IGC.0b013e318286665b.

PMID:
23370604
12.

Second-line Intraperitoneal Platinum-based Therapy Leads to an Increase in Second-line Progression-free Survival for Epithelial Ovarian Cancer.

Boisen MM, Lesnock JL, Richard SD, Beriwal S, Kelley JL, Zorn KK, Edwards RP.

Int J Gynecol Cancer. 2016 May;26(4):626-31. doi: 10.1097/IGC.0000000000000667.

PMID:
27051048
13.

Treatment of chemotherapy-induced anemia in ovarian cancer patients: does the use of erythropoiesis-stimulating agents worsen survival?

Rocconi RP, Sullivan P, Long B, Blaize M, Brown J, Arbuckle J, Bevis K, Estes JM, Reed E, Finan MA.

Int J Gynecol Cancer. 2012 Jun;22(5):786-91. doi: 10.1097/IGC.0b013e31825104f4.

PMID:
22552832
14.

The prognostic importance of p53, bcl-2, and bax in early stage epithelial ovarian carcinoma treated with adjuvant chemotherapy.

Skirnisdóttir I, Seidal T, Gerdin E, Sorbe B.

Int J Gynecol Cancer. 2002 May-Jun;12(3):265-76.

PMID:
12060448
15.

Impact of neoadjuvant chemotherapy cycles prior to interval surgery in patients with advanced epithelial ovarian cancer.

Colombo PE, Labaki M, Fabbro M, Bertrand M, Mourregot A, Gutowski M, Saint-Aubert B, Quenet F, Rouanet P, Mollevi C.

Gynecol Oncol. 2014 Nov;135(2):223-30. doi: 10.1016/j.ygyno.2014.09.002.

PMID:
25220627
16.

Progress in survival outcomes in patients with advanced ovarian cancer treated by neo-adjuvant platinum/taxane-based chemotherapy and late interval debulking surgery.

Stoeckle E, Bourdarias L, Guyon F, Croce S, Brouste V, Thomas L, Floquet A.

Ann Surg Oncol. 2014 Feb;21(2):629-36. doi: 10.1245/s10434-013-3278-x.

PMID:
24052318
17.

Phase II study of intraperitoneal carboplatin with intravenous paclitaxel in patients with suboptimal residual epithelial ovarian or primary peritoneal cancer: a Sankai Gynecology Cancer Study Group Study.

Fujiwara K, Nagao S, Kigawa J, Noma J, Akamatsu N, Miyagi Y, Numa F, Okada M, Aotani E.

Int J Gynecol Cancer. 2009 Jul;19(5):834-7. doi: 10.1111/IGC.0b013e3181a29dfe.

PMID:
19574769
18.

Prognostic significance of the number of postoperative intraperitoneal chemotherapy cycles for patients with advanced epithelial ovarian cancer.

Suidan RS, Zhou Q, Iasonos A, O'Cearbhaill RE, Chi DS, Long Roche KC, Tanner EJ, Denesopolis J, Barakat RR, Zivanovic O.

Int J Gynecol Cancer. 2015 May;25(4):599-606. doi: 10.1097/IGC.0000000000000389.

19.

Adjuvant platinum-based chemotherapy in patients with epithelial ovarian cancer: prognostic factors and final outcome.

Grivas A, Lianos E, Internos I, Papaxoinis G, Tselepatiotis E, Ziras N, Athanasiou AE.

J BUON. 2010 Oct-Dec;15(4):647-51.

PMID:
21229624
20.

Expression of TGFß1 and its receptors is associated with biological features of ovarian cancer and sensitivity to paclitaxel/carboplatin.

Komiyama S, Kurahashi T, Ishikawa M, Tanaka K, Komiyama M, Mikami M, Udagawa Y.

Oncol Rep. 2011 Apr;25(4):1131-8. doi: 10.3892/or.2011.1151.

PMID:
21249319
Items per page

Supplemental Content

Support Center